|
B/BE/25/BVW5 |
GenePHIT: A study to learn more about how well a new gene therapy (AB-1002) works and its safety in participants with congestive heart failure |
Humans |
Non-replicating recombinant vector derived from adeno-associated virus AAV2i8 carrying the transgene encoding for the human activated Inhibitor-1c ( I-1c) |
|
Only notified under the "contained use" procedure. Dossier submitted on 22/05/2023. |
A randomized, open-label, Phase 2 study evaluating lymphodepletion with fludarabine (F), cyclophosphamide (C), and ALLO-647 (A) vs FC alone, in subjects with R/R LBCL receiving ALLO-501A allogeneic CAR T cell therapy |
Humans |
CD19 CAR + knockouts CD52 and TRAC via TALEN technology |
|
Only notified under the "contained use" procedure. Dossier submitted on 09/06/1998. |
A phase II, multi-center, open label, randomized study to evaluate biodistribution and transmission, effectiveness and safety of two treatment regimens of Ad5CMV-p53 administered by intra-tumoral injections in 40 evaluable patients with advanced squamous |
Humans |
Wild-type p53 |
